Choice of HbA1c threshold for identifying individuals at high risk of type 2 diabetes and implications for diabetes prevention programmes: a cohort study by Rodgers, LR et al.
RESEARCH ARTICLE Open Access
Choice of HbA1c threshold for identifying
individuals at high risk of type 2 diabetes
and implications for diabetes prevention
programmes: a cohort study
Lauren R. Rodgers1* , Anita V. Hill2, John M. Dennis3, Zoe Craig4, Benedict May5, Andrew T. Hattersley6,
Timothy J. McDonald7, Rob C. Andrews3, Angus Jones3† and Beverley M. Shields3†
Abstract
Background: Type 2 diabetes (T2D) is common and increasing in prevalence. It is possible to prevent or delay T2D
using lifestyle intervention programmes. Entry to these programmes is usually determined by a measure of
glycaemia in the ‘intermediate’ range. This paper investigated the relationship between HbA1c and future diabetes
risk and determined the impact of varying thresholds to identify those at high risk of developing T2D.
Methods: We studied 4227 participants without diabetes aged ≥ 40 years recruited to the Exeter 10,000 population
cohort in South West England. HbA1c was measured at study recruitment with repeat HbA1c available as part of
usual care. Absolute risk of developing diabetes within 5 years, defined by HbA1c ≥ 48 mmol/mol (6.5%), according
to baseline HbA1c, was assessed by a flexible parametric survival model.
Results: The overall absolute 5-year risk (95% CI) of developing T2D in the cohort was 4.2% (3.6, 4.8%). This rose to
7.1% (6.1, 8.2%) in the 56% (n = 2358/4224) of participants classified ‘high-risk’ with HbA1c ≥ 39 mmol/mol (5.7%;
ADA criteria). Under IEC criteria, HbA1c ≥ 42 mmol/mol (6.0%), 22% (n = 929/4277) of the cohort was classified
high-risk with 5-year risk 14.9% (12.6, 17.2%). Those with the highest HbA1c values (44–47 mmol/mol [6.2–6.4%])
had much higher 5-year risk, 26.4% (22.0, 30.5%) compared with 2.1% (1.5, 2.6%) for 39–41 mmol/mol (5.7–5.9%)
and 7.0% (5.4, 8.6%) for 42–43 mmol/mol (6.0–6.1%). Changing the entry criterion to prevention programmes from
39 to 42 mmol/mol (5.7–6.0%) reduced the proportion classified high-risk by 61%, and increased the positive
predictive value (PPV) from 5.8 to 12.4% with negligible impact on the negative predictive value (NPV), 99.6% to
99.1%. Increasing the threshold further, to 44 mmol/mol (6.2%), reduced those classified high-risk by 59%, and
markedly increased the PPV from 12.4 to 23.2% and had little impact on the NPV (99.1% to 98.5%).
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Conclusions: A large proportion of people are identified as high-risk using current thresholds. Increasing the risk
threshold markedly reduces the number of people that would be classified as high-risk and entered into prevention
programmes, although this must be balanced against cases missed. Raising the entry threshold would allow limited
intervention opportunities to be focused on those most likely to develop T2D.
Keywords: Non-insulin treated type 2 diabetes, Progression, Disease prevention, Cohort analysis, EXTEND, Pre-
diabetes, HbA1c, Intermediate hyperglycaemia
Background
Type 2 diabetes (T2D) is both common and rapidly in-
creasing in prevalence. In 2017, an estimated 425 million
people were living with T2D, and this is projected to in-
crease to 629 million by 2030 [1, 2]. As T2D is poten-
tially preventable, the implementation of effective
strategies to prevent the development of T2D is a prior-
ity [3]. Trials have shown that prevention programmes
targeting those with the highest risk [4] may be effective
in delaying the onset of T2D [5–9] for up to 15 years.
While the relative merit of population vs targeted pre-
vention is a subject of much debate [10, 11], many coun-
tries have targeted programmes. Within Europe, 13/22
countries have current national diabetes prevention pro-
grammes (DPPs) in place; two-thirds of these specifically
target those at risk of developing diabetes [12]. Globally,
examples of countries with DPPs include Australia, USA
and China. While likely cost-effective, these programmes
require substantial investment, costing between 0.13 and
0.2% of the annual healthcare budgets of the
Netherlands, Germany and Australia [13, 14]. The UK
has launched a national DPP which is expected to cost
£105 million over a 5-year period [14–16].
A major issue for T2D prevention and the design of
prevention programmes is defining the at-risk group to
determine who should be enrolled. Entry to prevention
programmes is usually based on a measure of glycaemia
in the ‘intermediate’ range, often termed ‘pre-diabetes’
or ‘non-diabetic hyperglycaemia’. However, there is no
consensus as to which test, and at what threshold,
should be used to define pre-diabetes. The American
Diabetes Association (ADA) defines the elevated risk
range for pre-diabetes as an HbA1c 39–47mmol/mol
(5.7–6.4%), fasting plasma glucose (FPG) 5.6–6.9 mmol/
L or oral glucose tolerance test (OGTT) 2-h glucose of
7.0–11.1 mmol/L. The International Expert Committee
(IEC), World Health Organization (WHO) and many
other countries use ranges of HbA1c 42–47mmol/mol
(6.0–6.4%), FPG 6.0–6.9 mmol/L or OGTT 7–11.1
mmol/L to indicate a high risk of developing diabetes
[13]. Some guidelines, such as those in the UK [17], rec-
ommend a two-stage approach using a clinical risk score
and HbA1c 42–47mmol/mol (6.0–6.4%), where testing
is targeted to specific groups at high-risk (e.g., Leicester
Risk Score or Cambridge Risk Score) [18, 19].
In practice, opportune screening without a formal risk
assessment is commonly undertaken, with HbA1c the
most widely used measure due to ease of testing and
convenience [20]. Systematic reviews have concluded
this intermediate glycaemia predicts progression to T2D
with varying accuracy depending on the definition and
study population [6, 21–24]. A meta-analysis of studies
examining the relationship between HbA1c and future
diabetes identified 6 studies. They noted that progres-
sion rates using HbA1c ranges of 6.0–6.4% were similar
to those using FPG ranges 5.6–6.9 mmol/L and that fur-
ther studies on the predictive performance of HbA1c on
progression to T2D are required [22]. There has also
been criticism of the number of participants deemed to
be at risk of developing T2D using these tests. For ex-
ample, HbA1c testing using the IEC/WHO definitions of
risk of developing diabetes (HbA1c 42–47mmol/mol
[6.0–6.4%]) 19% of UK adults would be considered to be
at high risk of developing T2D, rising to 49% under the
ADA defined glycaemic range (HbA1c 39–47mmol/mol
[5.7–6.4%]) [25]. It is unlikely resources will ever be
available to enter this proportion of a population into an
effective diabetes prevention programme [26]. The UK
has 100,000 places, rising to 200,000, annually for their
programme [27], a fraction of the places that would be
needed to enrol the estimated 19% of the adult popula-
tion, ~ 8.5 million in England [28], who will have an
HbA1c ≥ 42mmol/mol (6.0%).
We use a large UK population dataset to assess how
best to target the people most at risk of developing T2D
for these prevention programmes. We evaluate the rela-
tionship between HbA1c and future diabetes risk in a
self-selected population cohort and determine the im-




Participant data were accessed via the Exeter 10,000/
Peninsula Research Bank (EXTEND/PRB). EXTEND/
PRB is an unselected population cohort of 11,074 partic-
ipants, 8295 without known diabetes, recruited from the
community and primary care in the South West, UK.
This is an ethically approved research cohort (REC no:
14/SW/1089) established to provide a resource for
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researchers seeking access to samples/data/potential re-
search participants [29]. It was designed to support re-
search into improving our understanding of common
diseases and healthy ageing. Participants were recruited
from GP practices through mail invites to adults regis-
tered with the practice, word of mouth, study promotion
at places of work, social groups and public events and
through local media. Baseline samples taken include
fasting blood and urine, with associated data recorded
including height, weight, blood pressure and lifestyle/
medical history details. Participants are invited to pro-
vide consent for further contact and access to ongoing
medical records. Follow-up blood test results were ob-
tained from electronic laboratory records for 10,885/11,
074 participants who provided consent.
Our entry criteria based on baseline EXTEND/PRB re-
cruitment included aged ≥ 40 years and no diagnosed
diabetes (either previously diagnosed or HbA1c ≥ 48
mmol/mol [6.5%] [30]). This identified 6434 individuals
(Fig. 1). An additional criterion for our study was that
individuals had at least one follow-up HbA1c > 4 weeks
after the baseline measurement. There were no add-
itional values (non-follow-up) on 2207 participants
(Additional file 1: Table S1). While HbA1c is not rou-
tinely measured in people without diabetes, in the UK, it
is measured as part of the UK NHS Health check for
those aged 40–74 years or through opportunistic screen-
ing [31]. Four thousand two hundred twenty-seven par-
ticipants with follow-up data were identified for our
study.
Cohort recruitment occurred between January 2010
and April 2018. Electronic laboratory records were
accessed up to March 2019.
Laboratory measurement
All included HbA1c values (baseline and follow-up) were
assessed by the Academic Department of Blood Sciences
at the Royal Devon and Exeter NHS Foundation Trust,
using the TOSOH G8Ion Exchange High Performance
Fig. 1 Flow chart of patients through the study
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Liquid Chromatography platform, calibrated to the IFCC
reference preparation, intra assay CV < 2%.
Statistical analysis
In the primary analysis, we fitted a flexible parametric
survival model to estimate the absolute risk and hazard
ratio (HR) of developing diabetes within 5 years given a
baseline HbA1c measurement. The flexible parametric
model was used, rather than Cox proportional hazards
regression, as risk increased more at higher HbA1c
values; this allowed for the fact that the proportional
hazards assumption would not be met. For this study,
we defined a diagnosis of diabetes as an HbA1c ≥ 48
mmol/mol (6.5%). For those who did not have an HbA1c
≥ 48mmol/mol (6.5%), data were censored at either their
last HbA1c (if within 5 years after baseline), or at 5 years
if they had further measurements. We evaluated the 5-
year risk of developing T2D using the existing HbA1c
ranges for identifying those at high risk of developing
diabetes; ADA (HbA1c 39–47 mmol/mol [5.7–6.4%]),
IEC/UK (42–47mmol/mol [6.0–6.4%]). We assessed the
area under the receiver operating characteristic curve
(AUC ROC), false positive and false negative rates, sensi-
tivity, specificity, positive predictive value (PPV) and
negative predictive value (NPV) for currently used
HbA1c thresholds and assessed the impact of raising the
threshold.
We also looked at the impact of combined HbA1c and
clinical risk score. The Leicester Risk Score (LRS) was
developed and validated on similar UK population co-
horts and is recommended in NHS guidance [17, 18].
The LRS model variables are sex, age (≤ 50, 50–60, 60–
70 and ≥ 70 years), a relative with diabetes (none and
first-degree family history of T2D), waist circumference
(< 90, 90–99, 99–110 and ≥ 110 cm), high blood pressure
(previous history of or participant on antihypertensive
medication) and BMI (< 25, 25–30, 30–35 and ≥ 35 kg/
m2). The risk of developing diabetes was modelled using
these covariates and an optimal cut point for high risk of
developing T2D was calculated using the model [19]; a
person with a LRS score ≥ 16 is considered at high risk
of developing T2D. In the UK, there are three pathways
to the DPP; a blood test results in the at-risk range as
part of routine clinical care, a LRS ≥ 16 followed by a
blood test result in the at-risk range or those who have
been in the at risk group in the past [32, 33]. The use of
a two-stage procedure with the clinical risk score (LRS)
reduces the need for additional blood testing in those at
low risk. LRS results are presented in Additional file 2.
As a DPP was introduced in the cohort area in June
2018, a sensitivity analysis with study end point June
2018 was carried out (Additional file 3).
Data were analysed using Stata v16 including the
stpm2 package.
Results
Within included participants (n = 4227), 3.4% (n = 144)
of participants progressed to diabetes within a 5-year
period. Mean (SD) time to progression to diabetes was
45.6 (17.9) months and mean follow-up time (SD) 28.4
(14.0) months (Table 1). Follow-up data were available
for 4227 out of 6434 participants who provided baseline
HbA1c. These participants had heavier BMI (mean 95%
CI difference 0.8 kg/m2 [0.6, 1.0 kg/m2] kg/m2) and were
3.7 years (3.1, 4.3 years) older. Their baseline HbA1c was
1.7 mmol/mol (1.5, 1.9 mmol/mol), 0.15% (0.14, 0.17%),
higher than those without follow-up (Table 1, Additional
file 1: Table S1), suggesting those who followed up with
clinical hbA1c testing had a higher risk of diabetes.
The absolute 5-year risk of developing type 2 diabetes is
modest in those meeting criteria for diabetes prevention
programmes
The overall absolute 5-year risk (95% CI) of developing
T2D in the cohort was 4.2% (3.6,4.8%). 56% (n = 2358/
4224) of participants were classified as high-risk based
on ADA criteria (HbA1c ≥ 39 mmol/mol [5.7%]). How-
ever, the risk of progression in this group was modest:
absolute 5-year risk of developing T2D 7.1% (6.1,8.2%).
Using the IEC criteria, HbA1c ≥ 42mmol/mol (6.0%),
22% (n = 929/4277) of the cohort was classified as ‘high-
risk’, the absolute 5-year risk in this group was 14.9%
(12.6, 17.2%). In those meeting both UK NICE criteria of
HbA1c ≥ 42 and LRS ≥ 16, 14% (n = 578/4214), the 5-
year risk was slightly higher at 19.0% (15.8,22.1%). In
those at high clinical risk (LRS ≥16), 56% of participants
identified as high-risk by US criteria had a low risk of
progression: the overall 5-year risk in those with HbA1c
≥ 39mmol/mol [5.7%] was 10.4% (8.7,12.1%) with risk
3.1% (2.0,4.0%) in the group with HbA1c 39–41mmol/
mol [5.7–5.9%].
Raising the HbA1c threshold for entry reduces the
number of people referred to prevention programmes
who are unlikely to develop diabetes
Figure 2a (values in Additional file 4) shows absolute
risk and Fig. 2b relative risks for developing HbA1c de-
fined diabetes within 5 years of study recruitment based
on a flexible parametric survival model. A Kaplan-Meier
plot by HbA1c categories is shown in Additional file 5.
Future risk of developing diabetes was very strongly
related to HbA1c value within the current ‘high-risk’
categories. Those in the lower ranges of current ‘pre-dia-
betes’ criteria had a low 5-year absolute risk of develop-
ing diabetes, even where multiple other risk factors were
present. For example, 5-year risk in those with the high-
est HbA1c values (44–47mmol/mol [6.2–6.4%]) was
26.4% (22.0, 30.5%) compared with 2.1% (1.5,2.6%) for
39–41mmol/mol (5.7–5.9%) and 7.0% (5.4, 8.6%) for
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those with an HbA1c 42–43mmol/mol (6.0–6.1%). The
hazard ratio (HR) shows that a person with an HbA1c of
44 mmol/mol (6.2%) is three times (CI 2.6–3.5) more
likely to develop T2D within 5 years than someone with
an HbA1c of 42 mmol (6.0%) (Fig. 2b).
Increasing the risk threshold reduced the number of
participants that would be classified as high-risk and en-
tered into prevention programmes and increased the risk
of included individuals (Table 2). Changing the US
threshold of 39 mmol/mol (5.7%) to the more widely
used threshold of 42 mmol/mol (6.0%) reduces the pro-
portion classified as high-risk (and therefore eligible for
intervention) by 61%. Increasing the threshold further
from 42 to 44mmol/mol (6.0% to 6.2%) reduces the pro-
portion classified as high-risk (and therefore eligible for
intervention) by a further 59%. While these changes
markedly increase positive predictive value and markedly
reduce false positive rates, they have very little impact
on the negative predictive value, with those below the
thresholds unlikely to develop diabetes within 5 years
(Table 2, Fig. 3). However, higher thresholds reduce sen-
sitivity, with 38.9% (30.9,47.3%) of those developing dia-
betes within 5 years missed using a threshold of > 44
mmol/mol (sensitivity 61.1% [52.6, 69.1%]). Figure 3 il-
lustrates the impact of these thresholds on screening a
population.
Combining assessment of a patient’s clinical risk with
their HbA1c test result only very modestly improves
prediction of future diabetes
The impact of combining clinic risk (using the LRS) with
HbA1c testing on our model of 5-year absolute risk is
shown in Additional file 2. Overall the 5-year absolute
risk for an LRS ≥ 16 was 5.5% (4.5, 6.5%, n = 1916),
slightly higher than the risk in the whole cohort, 4.2%
(3.6,4.8%, n=4227), and the 5-year risk was only mod-
estly higher in combination with high HbA1c. When
assessing the accuracy of the thresholds in our cohort,
using a LRS score of ≥ 16 alone had similar performance
to measuring HbA1c and using a cutoff of 39 mmol/mol
(5.7%), without the need for a biochemical test. How-
ever, the positive predictive value of both approaches
was low: 5.9% (4.9, 7.1%) (LRS ≥ 16, NPV 98.7% [98.1,
99.1%]) and 5.8% (4.9, 6.8%) (HbA1c ≥ 39mmol/mol
[5.7%], NPV 99.6% [99.2, 99.8%]). The performance of
the UK recommended two-step strategy is shown in
Table 1 Baseline characteristics of the cohort

























































Current smoker 5.6% (n = 235/4227) 5.4% (n = 219/4082) 11.1% (n = 16/144)
Family history of diabetes 21.7% (n = 918/4227) 21.4% (n = 841/4083) 30.6% (n = 44/144)
Ethnicity:
White 98.9% (n = 4180/4225) 98.9% (n = 4037/4081) 99.3% (n = 143/144)
Other 1.1% (n = 45/4225) 1.1% (n = 44/4081) 0.7% (n = 1/144)






Mean (SD) or percentage reported
aShorter follow-up time in those who progressed to diabetes vs those who did not is due to censoring of time at the point of progression to T2D
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Additional file 2 and improves the positive predictive
value from the use of an HbA1c of 42 mmol/mol (6.0%)
alone (from 12.4% [10.3, 14.7%] to 15.9% [13.0, 19.2%]),
at the expense of a decrease in sensitivity from 79.9%
(72.4, 86.1%) to 63.9% (55.5, 71.7%) but a negligible
change in NPV 99.1% (98.7, 99.4%) to 98.6% (98.1,
98.9%) (Supplementary Table S3).
Sensitivity analysis
A sensitivity analysis excluded any participants who may
have been affected by the start of the UK’s DPP (Add-
itional file 3), this reduced our cohort size to n=4105.
There were no appreciable changes in the demographic
characteristics of the cohort (Additional file 3: Table S4),
e.g., HbA1c changed from mean (SD) 38.8 mmol/mol
(3.5), 5.7% (0.3), to 38.9 mmol/mol (3.5), 5.7% (0.3). The
mean follow-up time was reduced from 45.0 months to
43.3 months. A similar proportion of participants pro-
gressed to T2D, 3.2% (n = 130/4105), and the absolute
risk of progression within 5 years was similar; at a
threshold of 39 mmol/mol (5.7%) the risk was 4.2% (3.6,
4.8%), 7.1% (6.1,8.2%) and 14.9% (12.6,17.2%) for thresh-
olds of 42 and 44 mmol/mol (6.0% and 6.2%),
respectively.
Discussion
We have shown in our UK population cohort that
current guidance for using HbA1c to identify those at
risk of future diabetes classifies a large proportion of the
population as high-risk (often termed pre-diabetes).
Overall, for many individuals, the absolute risk of devel-
oping diabetes over a 5-year period is very low, particu-
larly for those at the lower end of the ‘high-risk’ HbA1c
range. A potential approach to target those most at risk
would be to raise the inclusion threshold, which would
markedly reduce the numbers at low risk undergoing
intervention, at the expense of loss of sensitivity, with a
proportion of who progress to T2D missed by a move to
higher thresholds. Raising HbA1c thresholds from 39
mmol/mol to 42mmol/mol (5.7–6.0%; ADA) or from
Fig. 2 A Absolute 5-year risk of developing T2D (defined by HbA1c ≥ 48 mmol/mol [6.5%]) within 5 years given a baseline HbA1c modelled
using a flexible parametric survival model. B Hazard ratio for risk of developing type T2D (defined by HbA1c ≥ 48mmol/mol [6.5%]) within 5
years given a baseline HbA1c modelled using a flexible parametric survival model. The hazard ratio presented is relative to the cutoff value of 42
mmol/mol (6.0%). --- indicates hazard ratio of 1. HbA1c % conversion = 0.0915 × HbA1c mmol/mol + 2.15
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42mmol/mol to 44mmol/mol (6.0–6.2%; IEC and UK)
would avoid classifying a large proportion of the popula-
tion who have low absolute risk as having a pre-disease
state, and could potentially increase cost-effectiveness of
targeted prevention clinical programs and research stud-
ies where resources are insufficient to target the entire
at-risk population.
Longitudinal cohort studies mostly focus on FPG or
IGT, with only n = 6/70 studies in a meta-analysis of
progression to T2D using HbA1c to define pre-diabetes
[22]. A UK cohort study of 5735 participants had 1.3%
progressing to T2D over 3 years and showed an in-
creased risk of developing diabetes with increasing
HbA1c, 7 times greater risk of developing diabetes in the
group with HbA1c 42–46mmol/mol (6.0–6.4%) vs < 31
mmol/mol (5.0%) [34]. Most studies used the ADA or
IEC HbA1c or IFG ranges to identify individuals at high
risk of developing diabetes without additional focus on
the impact of raising the threshold higher than 42
mmol/mol (6.0%). Three studies outside the UK had
similar duration, 5 years in the Danish (Inter99, n =
4930) and Australian (AusDiab, n = 6012) studies and 6
years in the French DESIR (n = 3784) study [35]. These
studies found similar incidences of diabetes to our study,
2.3–3.1%; however, modestly lower sensitivities were re-
ported (65–78% using a threshold of 39 mmol/mol
[5.7%] and 38–45% at a threshold of 42 mmol/mol
[6.0%]). The increase in PPV observed with increasing
HbA1c thresholds was consistent with our findings, 5.9–
11% at ≥ 39mmol/mol (5.7%), 13–28% for ≥ 42 mmol/
mol (6.0%) and 27–44% for ≥ 46mmol/mol (6.4%).
Other work has concluded that prevention pro-
grammes should target those at the highest risk. In a re-
cent study of a UK prevention programme, Smith et al.
[36] conclude that to maximise the effectiveness
programme eligibility criteria should be adjusted to tar-
get more high-risk individuals. Zhuo et al. found lower-
ing fasting glucose thresholds lowered the cost-
effectiveness of programmes [37]. A cost-effectiveness
analysis by Thomas et al. suggests that the best value,
and best health benefits, for a prevention programme,
would be to prioritise obese (BMI ≥ 30 kg/m2) individ-
uals, those with the highest HbA1c in the pre-diabetes
range and aged 40–74 [38]. A higher HbA1c threshold
Fig. 3 Illustration of how many people in the cohort, n = 4227, who are considered at high risk of developing diabetes given different HbA1c
selection criteria and the proportion of those in, and excluded from, the diabetes prevention programme who would have gone on to develop
diabetes; * ADA threshold, † IEC threshold
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for entry to a prevention programme targets those at the
highest risk.
The strengths of this study include the use of a large
unselected population cohort and the assessment of clinical
risk using models and thresholds previously validated and
routinely used in this region. In particular, this study adds
to the understanding of the predictive capacity of HbA1c in
progression to T2D, identified as an area requiring further
research [17, 22]. A key limitation of our study is that
follow-up HbA1c relied on clinical testing and was there-
fore not available in all study participants. This may have
introduced bias as factors that influence the risk of T2D
may also influence whether a clinician screens for diabetes.
This is consistent with those who provided baseline data
only in our cohort who were on average 3.7 years younger,
1.9 kg lighter and had 1.7mmol/mol (0.15%) lower HbA1c,
than our cohort. This suggests higher-risk patients were
more likely to be followed up and therefore included in our
cohort, and we may therefore overestimate future diabetes
risk. However, the characteristics of included participants
are broadly consistent with previous UK population studies
of older adults reporting HbA1c, for example, the Norfolk
(n = 3921), Leicester (n = 6390) and ELSA (n = 5262) stud-
ies reported mean HbA1c of 36, 39 and 36mmol/mol (5.4,
5.7, 5.4%), BMI 30.1, 28.1 and 27.5 km/m2, and age 58.8,
57.3 and 65.8 years, respectively [18, 39, 40].
A further limitation is that our cohort contains limited
numbers of people of non-white ethnicity (consistent
with the population of this region) and predictive value
of HbA1c and performance of HbA1c thresholds may be
different in other ethnicities [6, 22, 25, 41]. For example,
Mostafa et al. showed that equivalent HbA1c thresholds
differed in a study on white Europeans and south Asians,
5.7% and 6.0%, respectively [25]. The progression rates
to diabetes based on an HbA1c 6.0–6.4% have been
shown to differ across ethnicities: incidence rate ratios
(95% CI) 0.21 (0.02,2.03) in Europe and 0.30 (0.02, 4.96)
in the Americas relative to Asia [22]. Further work
should replicate our study in cohorts with more diverse
ethnic profiles.
Lastly, we have used HbA1c for both risk prediction
and diagnosis. We may have seen a different relationship
had glucose-based measures been used to define dia-
betes, with potentially lower sensitivity had multiple
measures (such as OGTT) been used to define incident
diabetes. However, this closely reflects clinical practice—
in the UK, T2D is now diagnosed principally by HbA1c
testing, and almost all of those diagnosed will have had
an earlier HbA1c test. Fasting glucose is tested rarely
and glucose tolerance tests are used only in the setting
of detecting gestational diabetes.
Our findings have potential implications for clinical
practice. HbA1c is commonly used in practice to deter-
mine if a person should be identified as high risk (often
termed ‘pre-diabetes’) and referred to a DPP, and, with
current thresholds, a high proportion (up to 54% with
ADA criteria) would be eligible, with low 5-year risk of
diabetes for those with HbA1c in the lower part of ‘pre-
diabetes’ risk range. Currently, those in the pre-diabetes
range are given equal weighting for an invitation to a
prevention programme. Where resources or capacity are
constrained, higher thresholds could be used to refer to
these programs, with those with lower HbA1c poten-
tially offered monitoring of HbA1c with referral only if
HbA1c progresses to a higher risk range. However, this
would be balanced with a trade-off in cases missed. Ul-
timately, where resources and capacity allow, the optimal
choice of threshold should be based on detailed cost-
effectiveness analysis, taking into account multiple fac-
tors including the costs of preventable cases that may be
missed with higher test thresholds, program costs and
the potential negative impact of ‘false positive’ results.
Conclusion
In a UK population, a large proportion of people are
identified as high-risk using current thresholds, with
modest 5-year risk of diabetes. Increasing the risk
threshold markedly reduces the number of people that
would be classified as high-risk and entered into preven-
tion programmes, allowing limited intervention oppor-
tunities to be focused on those most likely to develop
T2D.
Abbreviations
ADA: American Diabetes Association; AUC ROC: Area under the receiver
operating characteristic curve; CI: Confidence interval; DPP: Diabetes
prevention programme; EXTEND: Exeter 10,000 cohort; FPG: Fasting plasma
glucose; IEC: International Expert Committee; IQR: Inter quartile range;
LRS: Leicester Risk Score; NHS: National Health Service; NICE: National
Institute for Health Care Excellence; NPV: Negative predictive value;
OGTT: Oral glucose tolerance test; pp: Per person; PPV: Positive predictive
value; PRB: Peninsula Research Bank; T2D: Type 2 diabetes; UK: United
Kingdom; WHO: World Health Organization
Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s12916-021-02054-w.
Additional file 1. Characteristics of those who provided baseline data
only.
Additional file 2. Leicester Risk Score.
Additional file 3. Sensitivity analysis excluding data after the launch of
the UK diabetes prevention programme.
Additional file 4. Absolute 5 year risk of developing Type 2 diabetes
given baseline HbA1c.
Additional file 5. Kaplan-Meier survival plot by HbA1c category.
Acknowledgements
The authors would like to thank Dr B Knight for her helpful comments and
the volunteers for dedicating their time to completing the study. The
authors would like to acknowledge the contribution of the admin, nurse,
medical and research staff at the NIHR Exeter Clinical Research Facility for
volunteer recruitment, data/sample collection. The views expressed are those
Rodgers et al. BMC Medicine          (2021) 19:184 Page 9 of 11
of the author(s) and not necessarily those of the NIHR or the Department of
Health and Social Care
Authors’ contributions
AVH had the initial idea for the study. ATH, AVH and TJM researched the
data. ZC and BM conducted initial data analysis. LRR conducted the main
data analysis and provided statistical expertise. LRR wrote the first draft of
the paper with assistance from AGJ and BMS. All authors contributed to the
research design and interpretation of the results and critical revision of the
manuscript for important intellectual content. All authors approved the final
version of the manuscript. LRR attests that all listed authors meet authorship
criteria and that no others meeting the criteria have been omitted. LRR is
the guarantor of this work and, as such, had full access to all the data in the
study and takes responsibility for the integrity of the data and the accuracy
of the data analysis. The manuscript is an honest, accurate and transparent
account of the study being reported that no important aspects of the study
have been omitted.
Funding
The NIHR Exeter Clinical Research Facility is a partnership between the
University of Exeter Medical School College of Medicine and Health, and
Royal Devon and Exeter NHS Foundation Trust. The EXTEND/PRB project is
supported by the National Institute for Health Research (NIHR) Exeter Clinical
Research Facility. AGJ is funded by an NIHR Clinician Scientist award (CS-
2015-15-018). JD is supported by an Independent Fellowship funded by
Research England’s Expanding Excellence in England (E3) fund. TJM is
funded by an NIHR Senior Clinical Lectureship.
Availability of data and materials
The authors do not have permission to share these data. Access to the
EXTEND/PRB resource is governed and approved by the Peninsula Research
Bank Steering Committee. Requests for access to original data should be in
the form of a formal application the Peninsula Research Bank details can be
found at: https://exetercrfnihr.org/about/exeter-10000-prb/.
Declarations
Ethics approval and consent to participate
This commitment to ensuring effective patient and public involvement in all
stages of research is central to projects undertaken within the Exeter Clinical
Research Facility [42]. The lay members of the committee were enthusiastic
on the project aims and voted overwhelmingly to support the research team
by approving access to the required data.
EXTEND/PRB ethical approval number: 14/SW/1089 (5-year extension




ZC reports grants and non-financial support from Celgene, grants and non-
financial support from Merck Sharpe & Dohme, grants and non-financial sup-
port from Amgen, grants and non-financial support from Takeda, outside the
submitted work.
Author details
1Institute of Health Research, University of Exeter Medical School, South
Cloisters, St Lukes Campus, Exeter EX1 2LU, UK. 2NIHR Exeter Clinical
Research Facility, Royal Devon & Exeter NHS Foundation Trust & University of
Exeter Medical School, Exeter, UK. 3Institute of Biomedical and Clinical
Science, College of Medicine and Health, University of Exeter, Exeter EX2
5DW, UK. 4Clinical Trials Research Unit, Leeds Institute of Clinical Trials
Research, University of Leeds, Leeds, West Yorkshire, UK. 5College of
Mathematics Engineering and Physical Science, University of Exeter, Exeter,
UK. 6Department of Diabetes and Endocrinology, Royal Devon and Exeter
NHS Foundation Trust, Exeter, UK. 7Academic Department of Blood Sciences,
Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
Received: 3 March 2021 Accepted: 7 July 2021
References
1. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge
AW, et al. IDF Diabetes Atlas: global estimates of diabetes prevalence for
2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–81.
2. Zhou B, Lu Y, Hajifathalian K, Bentham J, Di Cesare M, Danaei G, et al.
Worldwide trends in diabetes since 1980: a pooled analysis of 751
population-based studies with 4.4 million participants. Lancet. 2016;
387(10027):1513–30.
3. Gray LJ, Troughton J, Khunti K, Davies MJ. Let’s Prevent Diabetes: from idea
to implementation. Pract Diabetes. 2017;34(2):55–7.
4. The Diabetes Prevention Program (DPP) Research Group. The Diabetes
Prevention Program (DPP): description of lifestyle intervention. Diabetes
Care. 2002;25:2165–71.
5. Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT, et al.
Pharmacological and lifestyle interventions to prevent or delay type 2
diabetes in people with impaired glucose tolerance: systematic review and
meta-analysis. Br Med J. 2007;334(7588):299.
6. Barry E, Roberts S, Oke J, Vijayaraghavan S, Normansell R, Greenhalgh T.
Efficacy and effectiveness of screen and treat policies in prevention of type
2 diabetes: Systematic review and meta-analysis of screening tests and
interventions. BMJ. 2017;356:i6538.
7. Knowler W, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA,
et al. Reduction in the incidence of type 2 diabetes with lifestyle
intervention or metformin. N Engl J Med. 2002;346:393–403.
8. Lindström J, Peltonen M, Eriksson JG, Aunola S, Hämäläinen H, et al.
Determinants for the effectiveness of lifestyle intervention in the Finnish
Diabetes Prevention Study. Diabetes Care. 2008;31:854–62.
9. Nathan DM, Barrett-Connor E, Crandall JP, Edelstein SL, Goldberg RB, Horton
ES, et al. Long-term effects of lifestyle intervention or metformin on
diabetes development and microvascular complications over 15-year
follow-up: the Diabetes Prevention Program Outcomes Study. Lancet
Diabetes Endocrinol. 2015;3:866–75.
10. Wareham NJ. Mind the gap: efficacy versus effectiveness of lifestyle
interventions to prevent diabetes. Lancet Diabetes Endocrinol. 2015;3(3):
160–1.
11. Barry E, Roberts S, Finer S, Vijayaraghavan S, Greenhalgh T. Time to question
the NHS diabetes prevention programme. BMJ. 2015;351:h4717.
12. Richardson E, Zaletel J, Nolte E, On behalf of Joint Action CHRODIS. POLICY
BRIEF National Diabetes Plans in Europe: What lessons are there for the
prevention and control of chronic diseases in Europe? Available from:
https://www.euro.who.int/__data/assets/pdf_file/0009/307494/National-dia
betes-plans-Europe.pdf. Cited 2021 Jan 20.
13. Roberts S, Barry E, Craig D, Airoldi M, Bevan G, Greenhalgh T. Preventing
type 2 diabetes: systematic review of studies of cost-effectiveness of lifestyle
programmes and metformin, with and without screening, for pre-diabetes.
BMJ Open. 2017;7:e017184 BMJ Publishing Group.
14. National Health Service. NHS England impact analysis of implementing NHS
diabetes prevention programme, 2016 to 2021. Available from: https://www.
england.nhs.uk/wp-content/uploads/2016/08/impact-assessment-ndpp.pdf.
Cited 2021 May 4.
15. National Institute for Health and Care Excellence. Type 2 diabetes
prevention: population and community-level interventions. NICE guideline
PH35; 2011.
16. Gillett M, Brennan A, Blake L, Payne N, Goyder L, Buckley Woods H, et al.
Prevention of type 2 diabetes: preventing pre-diabetes among adults in
high-risk groups. Report on use of evidence from effectiveness reviews and
cost-effectiveness modelling. 2010. Available from: https://www.nice.org.uk/
guidance/ph35/evidence/report-on-costeffectiveness-evidence-and-
methods-for-economic-modelling-pdf-68912173. Cited 2021 May 13.
17. National Institute for Health and Care Excellence. PH38: type 2 diabetes:
prevention in people at high risk. NICE guideline PH38; 2012.
18. Gray LJ, Taub NA, Khunti K, Gardiner E, Hiles S, Webb DR, et al. The Leicester
Risk Assessment score for detecting undiagnosed type 2 diabetes and
impaired glucose regulation for use in a multiethnic UK setting. Diabet
Med. 2010;27:887–95.
19. Griffin SJ, Little PS, Hales CN, Kinmonth AL, Wareham NJ. Diabetes risk score:
towards earlier detection of type 2 diabetes in general practice. Diabetes
Metab Res Rev. 2000;16(3):164–71.
Rodgers et al. BMC Medicine          (2021) 19:184 Page 10 of 11
20. Kilpatrick ES, Atkin SL. Using haemoglobin A1c to diagnose type 2
diabetes or to identify people at high risk of diabetes. BMJ. 2014;348:
g2867.
21. Richter B, Hemmingsen B, Metzendorf M-I, Takwoingi Y. Development
of type 2 diabetes mellitus in people with intermediate hyperglycaemia.
Cochrane Database Syst Rev. 2018;(10) Art. No.:CD012661. https://doi.
org/10.1002/14651858.CD012661.pub2..
22. Morris DH, Khunti K, Achana F, Srinivasan B, Gray LJ, Davies MJ, et al.
Progression rates from HbA1c 6.0-6.4% and other prediabetes
definitions to type 2 diabetes: a meta-analysis. Diabetologia. 2013;56(7):
1489–93.
23. Beulens J, Rutters F, Rydén L, Schnell O, Mellbin L, Hart H, et al. Risk and
management of pre-diabetes. Eur J Prev Cardiol. 2019;26(2_suppl):47–54.
24. Schmidt MI, Bracco PA, Yudkin JS, Bensenor IM, Griep RH, Barreto SM, et al.
Intermediate hyperglycaemia to predict progression to type 2 diabetes
(ELSA-Brasil): an occupational cohort study in Brazil. Lancet Diabetes
Endocrinol. 2019;7(4):267–77.
25. Mostafa SA, Khunti K, Srinivasan BT, Webb D, Gray LJ, Davies MJ. The
potential impact and optimal cut-points of using glycated
haemoglobin, HbA1c, to detect people with impaired glucose
regulation in a UK multi-ethnic cohort. Diabetes Res Clin Pract. 2010;
90(1):100–8.
26. Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a
high-risk state for diabetes development. Lancet. 2012;379(9833):2279–90.
27. NHS England. NHS England impact analysis of implementing NHS diabetes
prevention programme, 2016 to 2021. 2016.
28. Office for National Statistics. Population estimates for the UK, England and Wales,
Scotland and Northern Ireland, provisional. Available from: https://www.ons.gov.
uk/peoplepopulationandcommunity/populationandmigration/populationestima
tes/bulletins/annualmidyearpopulationestimates/mid2019#toc. Cited 2020 Jun 4.
29. Exeter NIHR Clinical Research Facility: Exeter 10000. Available from: https://
exetercrfnihr.org/about/exeter-10000-prb/. Cited 2020 Jun 5.
30. World Health Organisation. Definition and diagnosis of diabetes mellitus
and intermediate hyperglycemia. 2006.
31. National Health Service. NHS health check. Available from: https://www.nhs.
uk/Conditions/nhs-health-check/. Cited 2020 Jun 10.
32. Public Health England, NHS England. NHS Diabetes Prevention Programme
NHSDPP overview and FAQ NHS England Publications Gateway Reference
05728. Available from: https://www.england.nhs.uk/wp-content/uploads/201
6/08/dpp-faq.pdf. Cited 2020 Jun 10.
33. Stokes J, Gellatly J, Bower P, Meacock R, Cotterill S, Sutton M, et al.
Implementing a national diabetes prevention programme in England:
lessons learned. BMC Health Serv Res. 2019;19(1):1–12.
34. Chamnan P, Simmons RK, Forouhi NG, Luben RN, Khaw KT, Wareham NJ,
et al. Incidence of type 2 diabetes using proposed HbA1c diagnostic criteria
in the european prospective investigation of cancer-norfolk cohort:
Implications for preventive strategies. Diabetes Care. 2011;34(4):950–6.
35. Soulimane S, Simon D, Shaw J, Witte D, Zimmet P, Vol S, et al. HbA1c,
fasting plasma glucose and the prediction of diabetes: Inter99, AusDiab and
D.E.S.I.R. Diabetes Res Clin Pract. 2011;96(3):392–9.
36. Smith JR, Greaves CJ, Thompson JL, Taylor RS, Jones M, Armstrong R, et al.
The community-based prevention of diabetes (ComPoD) study: a
randomised, waiting list controlled trial of a voluntary sector-led diabetes
prevention programme. Int J Behav Nutr Phys Act. 2019;16(1):112.
37. Zhuo X, Zhang P, Kahn HS, Gregg EW. Cost-effectiveness of alternative
thresholds of the fasting plasma glucose test to identify the target
population for type 2 diabetes prevention in adults aged ≥45 years.
Diabetes Care. 2013;36(12):3992–8.
38. Thomas C, Sadler S, Breeze P, Squires H, Gillett M, Brennan A. Assessing the
potential return on investment of the proposed UK NHS diabetes
prevention programme in different population subgroups: an economic
evaluation. BMJ Open. 2017;7(8):e014953.
39. Kumaravel B, Bachmann MO, Murray N, Dhatariya K, Fenech M, John WG,
et al. Use of haemoglobin A1c to detect impaired fasting glucose or type 2
diabetes in a United Kingdom community based population. Diabetes Res
Clin Pract. 2012;96(2):211–6.
40. Schöttker B, Rathmann W, Herder C, Thorand B, Wilsgaard T, Njølstad I, et al.
HbA1c levels in non-diabetic older adults - No J-shaped associations with
primary cardiovascular events, cardiovascular and all-cause mortality after
adjustment for confoundersin a meta-analysis of individual participant data
from six cohort studies. BMC Med. 2016;14(1):1–17.
41. Christensen DL, Witte DR, Kaduka L, Jørgensen ME, Borch-Johnsen K, Mohan V,
et al. Moving to an A1C-based diagnosis of diabetes has a different impact on
prevalence in different ethnic groups. Diabetes Care. 2010;33(3):580–2.
42. Exeter NIHR Clinical Research Facility: Patient and Public Involvement.
Available from: https://exetercrfnihr.org/public-and-patients/patient-and-
public-involvement-ppi/. Cited 2020 May 6.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Rodgers et al. BMC Medicine          (2021) 19:184 Page 11 of 11
